TG Therapeutics Posts Strong Q3 Revenue Gains
On January 15, Goldman Sachs raised its price target on TG Therapeutics to $39 from $37 while maintaining a Neutral rating after the company disclosed 2026 revenue guidance of $875–$900 million and faster-than-expected Phase 3 enrollment for subcutaneous BRIUMVI. TG reported Q3 2025 revenue of $161.7 million, GAAP net income of $390.9 million, and U.S. BRIUMVI sales of about $153 million.
Scoring Rationale
Moderate investor relevance and official earnings data boost score; limited novelty and low AI/DS relevance constrain impact.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalGoldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidanceinsidermonkey.com
